ABSTRACT
Rilpivirine (TMC278; RPV) is a second-generation, diarylpyrimidine (DAPY)-class, nonnucleoside reverse transcriptase inhibitor (NNRTI) initially developed by Tibotec Pharmaceuticals (currently Janssen Pharmaceuticals) for the treatment of HIV-1 infection. RPV is marketed as Edurant by Janssen Therapeutics, a subsidiary of Johnson & Johnson. A fixed-dose combination tablet of (tenofovir disoproxil fumarate [TDF], emtricitabine [FTC] and RPV is marketed by Gilead as Complera and Eviplera (these two tablets are apparently entirely equivalent despite different names). And as of early 2016, the USA FDA approved a fixed-dose combination tablet of TAF (tenofovir alafenamide), FTC, and RPV as Odefsey.
